Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study to explore the combination of Revlimid®, oral cyclophosphamide and
prednisone (RCP) in patients with newly diagnosed multiple myeloma.